MX2019001577A - Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal. - Google Patents

Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.

Info

Publication number
MX2019001577A
MX2019001577A MX2019001577A MX2019001577A MX2019001577A MX 2019001577 A MX2019001577 A MX 2019001577A MX 2019001577 A MX2019001577 A MX 2019001577A MX 2019001577 A MX2019001577 A MX 2019001577A MX 2019001577 A MX2019001577 A MX 2019001577A
Authority
MX
Mexico
Prior art keywords
lysosomal storage
pharmaceutical compositions
storage disorders
uses directed
directed
Prior art date
Application number
MX2019001577A
Other languages
English (en)
Inventor
Strupp Michael
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1613828.1A external-priority patent/GB201613828D0/en
Priority claimed from GBGB1702552.9A external-priority patent/GB201702552D0/en
Priority claimed from GBGB1705762.1A external-priority patent/GB201705762D0/en
Priority claimed from GBGB1706854.5A external-priority patent/GB201706854D0/en
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of MX2019001577A publication Critical patent/MX2019001577A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción proporciona el tratamiento de los trastornos del almacenamiento lisosomal (LSD), que comprende administrar acetil-leucina o una sal farmacéuticamente aceptable de la misma.
MX2019001577A 2016-08-11 2017-08-11 Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal. MX2019001577A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1613828.1A GB201613828D0 (en) 2016-08-11 2016-08-11 Therapeutic agents for lysosomal storage disorders
GBGB1702552.9A GB201702552D0 (en) 2017-02-16 2017-02-16 Therapeutic agents for lysosomal storage disorders
GBGB1705762.1A GB201705762D0 (en) 2017-04-10 2017-04-10 Therapeutic agents for lysosomal storage disorders
GBGB1706854.5A GB201706854D0 (en) 2017-04-28 2017-04-28 Therapeutic agents for lysosomal storage disorders
PCT/IB2017/054928 WO2018029657A1 (en) 2016-08-11 2017-08-11 Pharmaceutical compositions and uses directed to lysosomal storage disorders

Publications (1)

Publication Number Publication Date
MX2019001577A true MX2019001577A (es) 2019-08-29

Family

ID=59859423

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019001577A MX2019001577A (es) 2016-08-11 2017-08-11 Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
MX2021008432A MX2021008432A (es) 2016-08-11 2019-02-07 Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021008432A MX2021008432A (es) 2016-08-11 2019-02-07 Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.

Country Status (28)

Country Link
US (3) US11400067B2 (es)
EP (4) EP3359146B1 (es)
JP (3) JP7393943B2 (es)
KR (3) KR102467953B1 (es)
CN (1) CN109843275A (es)
AU (2) AU2017308864B2 (es)
BR (1) BR112019002719A2 (es)
CA (1) CA3033557A1 (es)
CY (2) CY1121345T1 (es)
DK (2) DK3359146T3 (es)
ES (2) ES2716133T3 (es)
HK (1) HK1253282B (es)
HR (2) HRP20190344T1 (es)
HU (2) HUE052837T2 (es)
IL (1) IL264610A (es)
LT (2) LT3359146T (es)
MA (2) MA55947A (es)
MD (2) MD3359146T2 (es)
ME (1) ME03340B (es)
MX (2) MX2019001577A (es)
PL (2) PL3482754T3 (es)
PT (2) PT3482754T (es)
RS (2) RS58478B1 (es)
RU (2) RU2021115932A (es)
SG (1) SG11201901048VA (es)
SI (2) SI3482754T1 (es)
TN (1) TN2019000032A1 (es)
WO (1) WO2018029657A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3482754T1 (sl) * 2016-08-11 2021-04-30 Intrabio Ltd Farmacevtski sestavki in uporabe usmerjene v motnje lizosomalnega shranjevanja
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
CN113348018A (zh) * 2018-12-06 2021-09-03 内在生物技术有限公司 乙酰基-亮氨酸的氘代类似物
WO2020178721A1 (en) 2019-03-02 2020-09-10 Intrabio Ltd. Leucine, acetyl leucine, and related analogs for treating disease
US20220362189A1 (en) 2019-06-28 2022-11-17 Intrabio Ltd. Combination therapy with acetyl-leucine and miglustat
WO2022264037A1 (en) * 2021-06-14 2022-12-22 Intrabio Ltd. Branched-chain amino acid derivatives to treat disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2749512B1 (fr) * 1996-06-10 1999-08-13 Pf Medicament Utilisation de l'acetyl dl leucine pour le traitement des tremblements
WO2001097829A2 (en) 2000-06-19 2001-12-27 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
FR2883180B1 (fr) 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
WO2009114729A2 (en) * 2008-03-14 2009-09-17 Irm Llc Compounds, compositions and methods for treating lysosomal storage diseases and disorders
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
GB201114017D0 (en) * 2011-08-15 2011-09-28 Univ Dundee Inhibitors against endosomal/ysosomal enzymes
JP2015518872A (ja) 2012-06-06 2015-07-06 フォンダッツィオーネ・テレソン アロステリックシャペロンおよびその使用
SI3482754T1 (sl) * 2016-08-11 2021-04-30 Intrabio Ltd Farmacevtski sestavki in uporabe usmerjene v motnje lizosomalnega shranjevanja
SI3416631T1 (sl) * 2016-08-11 2019-09-30 Intrabio Ltd Terapevtska sredstva za nevrodegenerativne bolezni

Also Published As

Publication number Publication date
JP7393943B2 (ja) 2023-12-07
CA3033557A1 (en) 2018-02-15
DK3482754T3 (da) 2021-02-01
SI3482754T1 (sl) 2021-04-30
EP3359146B1 (en) 2019-01-23
HK1253282A1 (zh) 2019-06-14
KR20190039226A (ko) 2019-04-10
SI3359146T1 (sl) 2019-05-31
PL3359146T3 (pl) 2019-07-31
PT3359146T (pt) 2019-03-27
EP3359146A1 (en) 2018-08-15
CY1123844T1 (el) 2022-05-27
AU2017308864B2 (en) 2023-06-01
DK3359146T3 (en) 2019-04-08
JP2022050564A (ja) 2022-03-30
MD3359146T2 (ro) 2019-04-30
RU2019106493A (ru) 2020-09-11
HRP20190344T1 (hr) 2019-04-19
EP3482754A1 (en) 2019-05-15
MA43876A (fr) 2018-08-15
RS58478B1 (sr) 2019-04-30
CY1121345T1 (el) 2020-05-29
TN2019000032A1 (en) 2020-07-15
HRP20210153T1 (hr) 2021-05-28
MD3482754T2 (ro) 2021-05-31
EP4342461A3 (en) 2024-05-29
JP2019524821A (ja) 2019-09-05
US11400067B2 (en) 2022-08-02
AU2017308864A1 (en) 2019-02-21
MA43876B1 (fr) 2019-04-30
HUE041914T2 (hu) 2019-06-28
US20240197663A1 (en) 2024-06-20
US20190201359A1 (en) 2019-07-04
RS61442B1 (sr) 2021-03-31
PL3482754T3 (pl) 2021-07-05
ME03340B (me) 2019-10-20
RU2021115932A (ru) 2021-06-08
CN109843275A (zh) 2019-06-04
KR20220154849A (ko) 2022-11-22
ES2849566T3 (es) 2021-08-19
PT3482754T (pt) 2021-02-03
MX2021008432A (es) 2021-08-19
RU2019106493A3 (es) 2020-10-26
RU2749515C2 (ru) 2021-06-11
MA55947A (fr) 2022-03-23
WO2018029657A1 (en) 2018-02-15
HK1253282B (zh) 2020-02-07
AU2023202903A1 (en) 2023-05-25
IL264610A (en) 2019-02-28
LT3359146T (lt) 2019-04-25
SG11201901048VA (en) 2019-03-28
EP3482754B1 (en) 2020-12-23
ES2716133T3 (es) 2019-06-10
EP4342461A2 (en) 2024-03-27
LT3482754T (lt) 2021-05-10
KR20220044372A (ko) 2022-04-07
EP3865126A1 (en) 2021-08-18
US20220331278A1 (en) 2022-10-20
JP2024059863A (ja) 2024-05-01
BR112019002719A2 (pt) 2019-05-14
KR102467953B1 (ko) 2022-11-16
KR102412724B1 (ko) 2022-06-23
HUE052837T2 (hu) 2021-05-28

Similar Documents

Publication Publication Date Title
MX2021008432A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
CA2956871C (en) Compounds active towards bromodomains
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
MY189466A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
PH12019501970A1 (en) Pharmaceutical compositions for combination therapy
MX2016012262A (es) Cenicriviroc para el tratamiento de fibrosis.
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
PH12019501301A1 (en) Pharmaceutical compositions for combination therapy
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
WO2016144706A3 (en) Autotaxin inhibitor compounds and uses thereof
WO2016144704A3 (en) Heterocyclic autotaxin inhibitor compounds
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
WO2017210527A8 (en) Autotaxin inhibitors
PH12020500472A1 (en) Autotaxin inhibitor compounds
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.
WO2016164719A3 (en) Methods used to treat cancer
MX2017001512A (es) Compuestos activos hacia bromodominios.